ANP's priority review voucher is looking nice, very nice indeed.
Here is Serapta's recent quarterly earnings update.
https://seekingalpha.com/news/37254...cs-narrows-q2-net-loss-thanks-to-one-off-gain
Within the quarter - Serapta sold one of their Priority Review Vouchers for A$140m.
A$140m is more than our entire market cap.
So, whats the value of our 20 years of clinical data, 3 x successful PH2a results, big pharma interest, fast track(soon), EMA and FDA advancements, CSL chair, etc, worth?
ANP's priority review voucher is looking nice, very nice indeed....
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.7¢ | $134.7K | 1.732M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99278 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 122500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.0¢ | 7.7¢ | 70281 | ||
| Last updated 15.51pm 07/05/2024 ? | |||||
| PER (ASX) Chart |